{"id":"irbesartan-hctz","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Dizziness"},{"rate":"3-5","effect":"Fatigue"},{"rate":"1-3","effect":"Hyperkalemia (elevated potassium)"},{"rate":"2-4","effect":"Hypokalemia (low potassium)"},{"rate":"1-2","effect":"Hyperuricemia (elevated uric acid)"},{"rate":"2-4","effect":"Headache"},{"rate":"1-3","effect":"Orthostatic hypotension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Irbesartan is an angiotensin II receptor blocker (ARB) that prevents angiotensin II from binding to AT1 receptors on blood vessels, causing vasodilation and reduced vasoconstriction. Hydrochlorothiazide (HCTZ) is a thiazide diuretic that increases sodium and water excretion, reducing blood volume and cardiac output. Together, these complementary mechanisms provide additive antihypertensive effects.","oneSentence":"Irbesartan blocks angiotensin II receptors to lower blood pressure, while hydrochlorothiazide acts as a thiazide diuretic to reduce fluid volume.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:17:09.152Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension (high blood pressure)"},{"name":"Reduction of cardiovascular events in hypertensive patients at high risk"}]},"trialDetails":[{"nctId":"NCT06790927","phase":"NA","title":"Standardized Antihypertensive Treatment Protocol","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2025-02-24","conditions":"Hypertension","enrollment":400},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213},{"nctId":"NCT03006796","phase":"","title":"Observational Study of Azilsartan/Chlorthalidone and Irbesartan/Hydrochlorothiazide in Hypertension and Obesity.","status":"COMPLETED","sponsor":"Russian Heart Failure Society","startDate":"2017-01-16","conditions":"Arterial Hypertension","enrollment":94},{"nctId":"NCT00535925","phase":"PHASE4","title":"Nephropathy In Type 2 Diabetes and Cardio-renal Events","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2005-10","conditions":"Diabetic Nephropathy","enrollment":850},{"nctId":"NCT04330300","phase":"PHASE4","title":"Coronavirus (COVID-19) ACEi/ARB Investigation","status":"SUSPENDED","sponsor":"National University of Ireland, Galway, Ireland","startDate":"2020-04-30","conditions":"Hypertension, COVID-19","enrollment":2414},{"nctId":"NCT01712126","phase":"NA","title":"Crossover Bioequivalence Study of Irbesartan Hydrochlorothiazide 300/25 mg Tablets Under Fed Conditions","status":"COMPLETED","sponsor":"Roxane Laboratories","startDate":"2007-09","conditions":"Hypertension","enrollment":40},{"nctId":"NCT01712139","phase":"NA","title":"Crossover Bioequivalence Study of Irbesartan HCTZ 300/25 mg Tablets Under Fasted Conditions","status":"COMPLETED","sponsor":"Roxane Laboratories","startDate":"2007-09","conditions":"Hypertension","enrollment":37},{"nctId":"NCT00219115","phase":"PHASE3","title":"A Clinical Study to Compare Combination of Aliskiren+ HCTZ to Irbesartan+ HCTZ or Amlodipine+ HCTZ or HCTZ Alone in Obese Hypertensive Not Responsive to HCTZ 25 mg","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-01","conditions":"Hypertension","enrollment":493},{"nctId":"NCT00987662","phase":"PHASE4","title":"Irbesartan Versus Amlodipine: The OBI Study","status":"WITHDRAWN","sponsor":"Aristotle University Of Thessaloniki","startDate":"2012-01","conditions":"Obesity, Hypertension","enrollment":""},{"nctId":"NCT01858610","phase":"NA","title":"Drug Interaction Between Irbesartan and Hydrochlorothiazide","status":"COMPLETED","sponsor":"Damanhour University","startDate":"2013-03","conditions":"Healthy","enrollment":18},{"nctId":"NCT00713011","phase":"PHASE3","title":"Adalat XL vs Diltiazem on Proteinuria and Blood Pressure in Hypertensive Diabetic Patients","status":"WITHDRAWN","sponsor":"Bayer","startDate":"2008-11","conditions":"Diabetic Nephropathies, Hypertension","enrollment":""},{"nctId":"NCT00741702","phase":"NA","title":"Diabetes Risk Evaluation and Microalbuminuria in Saskatchewan First Nations Peoples","status":"COMPLETED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2001-09","conditions":"Hypertension, Diabetes Mellitus","enrollment":95},{"nctId":"NCT00362037","phase":"PHASE4","title":"I SELECT - Irbesartan In Hypertensive Patients With Left Ventricular Hypertrophy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-03","conditions":"Hypertension","enrollment":281},{"nctId":"NCT00095394","phase":"PHASE3","title":"Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe Hypertension","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2004-09","conditions":"Hypertension","enrollment":645},{"nctId":"NCT00095550","phase":"PHASE3","title":"Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy for Patients With Moderate Hypertension","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2004-10","conditions":"Hypertension","enrollment":496},{"nctId":"NCT00110422","phase":"PHASE4","title":"Irbesartan in the Treatment of Hypertensive Patients With Metabolic Syndrome","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2005-11","conditions":"Metabolic Syndrome, Hypertension","enrollment":400},{"nctId":"NCT00362258","phase":"PHASE4","title":"I PREVENT - Irbesartan In Hypertensive Diabetic Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-02","conditions":"Hypertension","enrollment":797},{"nctId":"NCT00335673","phase":"PHASE4","title":"I SAVE - Irbesartan in Mild to Moderate Hypertensive Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-02","conditions":"Hypertension","enrollment":1630},{"nctId":"NCT00224549","phase":"PHASE4","title":"PHARES Study: Management of Resistant Hypertension","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2005-04","conditions":"Hypertension","enrollment":180},{"nctId":"NCT00500604","phase":"PHASE4","title":"Efficacy of Irbesartan/Hydrochlorothiazide Versus Valsartan/Hydrochlorothiazide in Mild to Moderate Hypertension","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-07","conditions":"Hypertension","enrollment":1617},{"nctId":"NCT00708344","phase":"PHASE4","title":"ACTUAL: Efficacy and Safety of Irbesartan/Hydrochlorothiazide Combination","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-06","conditions":"Hypertension","enrollment":832},{"nctId":"NCT00443612","phase":"PHASE4","title":"Irbesartan/Hydrochlorothiazide National Taiwan University Hospital Listing","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-09","conditions":"Hypertension","enrollment":60},{"nctId":"NCT00670566","phase":"PHASE4","title":"Irbesartan/Hydrochlorothiazide to Control Elevated Blood Pressure to Target in Moderate to Severe Hypertensive Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-04","conditions":"Hypertension","enrollment":503},{"nctId":"NCT00847834","phase":"PHASE4","title":"Irbesartan-Hydrochlorothiazide Phase IV Study: Treatment of Hypertension in Chinese Population","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-12","conditions":"Hypertension","enrollment":968},{"nctId":"NCT00684489","phase":"NA","title":"Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2003-09","conditions":"Hypertension","enrollment":52},{"nctId":"NCT00264212","phase":"PHASE4","title":"AMISH : Aprovel for Management of Isolated Systolic Hypertension","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-08","conditions":"Hypertension","enrollment":436},{"nctId":"NCT00263003","phase":"PHASE3","title":"Irbesartan/Hydrochlorothiazide and Irbesartan in the Treatment of Mild to Moderate Hypertension","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-06","conditions":"Hypertension","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":40,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Avapro"],"phase":"phase_3","status":"active","brandName":"Irbesartan/HCTZ","genericName":"Irbesartan/HCTZ","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Irbesartan blocks angiotensin II receptors to lower blood pressure, while hydrochlorothiazide acts as a thiazide diuretic to reduce fluid volume. Used for Hypertension (high blood pressure), Reduction of cardiovascular events in hypertensive patients at high risk.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}